Hyperfine structure

Hyperfine, Inc. Continues Global Market Expansion by Entering Into a Distribution Partnership with Radiosurgery Global, Ltd. to Bring the Swoop® System to India

Retrieved on: 
화요일, 5월 28, 2024
Health, Technology, Photography, Health Technology, Radiology, Hardware, Partnership, CE, Patient, UKCA, Google Images, Prevalence, Brain, FDA, MRI, Trauma, Stroke, MDR, Certification, Hyperfine structure, Nursing care plan, CDSCO, Medical imaging

The distribution agreement also includes the countries of Malaysia, Indonesia, and Singapore through future expansion, offering Hyperfine, Inc. a significantly increased presence in Asia.

Key Points: 
  • The distribution agreement also includes the countries of Malaysia, Indonesia, and Singapore through future expansion, offering Hyperfine, Inc. a significantly increased presence in Asia.
  • The clinical value of the Swoop® system is applicable globally as Hyperfine, Inc. aims to expand overall access and availability of MRI.
  • The expansion into global markets is supported by the company’s strong track record of securing international approvals for the Swoop® system.
  • Hyperfine, Inc. plans to continue its commercial expansion in partnership with Radiosurgery Global, Ltd. supporting future marketing submissions in India.

Hyperfine, Inc. to Present at the Jefferies Global Healthcare Conference

Retrieved on: 
수요일, 5월 22, 2024
Health Technology, Health, Neurology, Medical Devices, Conference, FDA, Hyperfine structure

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced plans to present at the upcoming Jefferies Global Healthcare Conference, in New York, NY.

Key Points: 
  • Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced plans to present at the upcoming Jefferies Global Healthcare Conference, in New York, NY.
  • Members of management are scheduled to present on Thursday, June 6, 2024, at 3:00 pm ET.
  • The webcasts will be archived and available for replay for at least 90 days after the event.
  • For more information about the Swoop® Portable MR Imaging® system, please visit hyperfine.io .

Hyperfine, Inc. to Announce First Quarter 2024 Financial Results on May 13, 2024

Retrieved on: 
월요일, 4월 29, 2024
Health Technology, Health, Neurology, Medical Devices, FDA, Hyperfine structure

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced that it will report financial results for the first quarter 2024 on Monday, May 13, 2024.

Key Points: 
  • Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced that it will report financial results for the first quarter 2024 on Monday, May 13, 2024.
  • Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
  • A live audio webcast and an archive of the presentation will be available through the Investors page of Hyperfine, Inc.’s corporate website at https://investors.hyperfine.io/ .
  • Participants are encouraged to register more than 15 minutes before the start of the call.

Hyperfine, Inc. Takes the Stage at ISMRM with Seventeen Abstracts Assessing the Potential of Using Swoop® System Images Across Multiple Care Settings and Clinical Conditions

Retrieved on: 
화요일, 4월 23, 2024
Medical Devices, Health, Neurology, Health Technology, Clinical Trials, Radiology, FDA, Brain, International Society, Amyloid-related imaging abnormalities, ARIA, Abstract, Conference, CARE, Patient, Magnetic resonance, Observational study, Physician, Multiple sclerosis, Hyperfine structure, Biomarker, Medical imaging

These seventeen abstracts span a wide variety of use cases, including two that highlight the utility of brain images acquired with the ultra-low-field Swoop® Portable MR Imaging® system to aid physicians screening for various biomarkers and monitoring disease progression unique to neurodegenerative diseases, including Alzheimer’s and multiple sclerosis (MS).

Key Points: 
  • These seventeen abstracts span a wide variety of use cases, including two that highlight the utility of brain images acquired with the ultra-low-field Swoop® Portable MR Imaging® system to aid physicians screening for various biomarkers and monitoring disease progression unique to neurodegenerative diseases, including Alzheimer’s and multiple sclerosis (MS).
  • Conference attendees can learn more during these select presentations:
    “These abstracts are very encouraging.
  • Earlier this month, the company announced that the first patients have been scanned in the CARE PMR (Capturing ARIA Risk Equitably with Portable MR) study.
  • For more information about the Swoop® Portable MR Imaging® system, please visit hyperfine.io.

Leading Institutions Enroll First Alzheimer’s Patients Receiving Amyloid-Targeting Therapy in CARE PMR Study

Retrieved on: 
수요일, 4월 17, 2024
Medical Devices, FDA, Health, Health Technology, Clinical Trials, General Health, Brain, Patient, Bleeding, Amyloid-related imaging abnormalities, Mass, ARIA, Workflow, Dementia, CARE, DRS, Radiology, Observational study, Physician, PMR, MRI, Multimedia, Hyperfine structure, Mass General Brigham, Medical imaging

Patients with Alzheimer’s can now be treated with amyloid-targeting therapy, which reduces the amyloid plaque burden in the brain.

Key Points: 
  • Patients with Alzheimer’s can now be treated with amyloid-targeting therapy, which reduces the amyloid plaque burden in the brain.
  • Teresa Gomez-Isla and W. Taylor Kimberly, will evaluate the Swoop® system to understand its potential role in the overall continuum of Alzheimer’s care.
  • “The newly approved amyloid-targeting therapy represents a major milestone in the global fight against Alzheimer’s, bringing hope of additional years of independent living to patients.
  • The required MRI scans to image brain abnormalities in patients receiving amyloid-targeting therapy present workflow challenges for patients and providers,” said Hyperfine, Inc. President and CEO Maria Sainz.

Hyperfine, Inc. Collaborates with King’s College London to Demonstrate the Swoop® System and UNITY Project to The Princess Royal

Retrieved on: 
화요일, 3월 12, 2024
Research, Medical Devices, Neurology, Hospitals, Health Technology, Radiology, Health, General Health, Science, Mother, HRH, Princess Royal, Brain, King, MRI, Bill, Hyperfine structure, National Health Service, NHS, Ultra, Quality of life, King's College London, Multimedia, Royal Highness, FDA, School, Medical imaging

Her Royal Highness was shown a demonstration of the Swoop® system to see first-hand the device’s ease of use.

Key Points: 
  • Her Royal Highness was shown a demonstration of the Swoop® system to see first-hand the device’s ease of use.
  • “It is a great pleasure for us to introduce HRH Princess Royal to the UNITY project.
  • “Since 2021, the Hyperfine, Inc. collaboration with King’s College London has further enabled our vision of making brain MRI accessible anywhere in the world to become a reality at UNITY project sites,” said Ms. Sainz.
  • The center also provides National Health Service (NHS) services under the South London and Maudsley NHS Foundation Trust.

Hyperfine, Inc. to Announce Fourth Quarter and Full Year 2023 Financial Results on March 21, 2024

Retrieved on: 
목요일, 3월 7, 2024
Health, Medical Devices, Technology, General Health, Pharmaceutical, Hardware, Biotechnology, FDA, Hyperfine structure

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the world’s first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system, today announced that it will report financial results for the fourth quarter and full year 2023 on Thursday, March 21, 2024.

Key Points: 
  • Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the world’s first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system, today announced that it will report financial results for the fourth quarter and full year 2023 on Thursday, March 21, 2024.
  • Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
  • A live audio webcast and an archive of the presentation will be available through the Investors page of Hyperfine, Inc.’s corporate website at https://investors.hyperfine.io/ .
  • Participants are encouraged to register more than 15 minutes before the start of the call.

Hyperfine, Inc. to Present at the Oppenheimer 34th Annual Healthcare Conference

Retrieved on: 
수요일, 2월 28, 2024
Health Technology, Health, Neurology, Medical Devices, FDA, Hyperfine structure, Medtech, Conference

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the world’s first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system, today announced plans to present at the upcoming Oppenheimer 34th Annual Healthcare MedTech & Services Conference, taking place virtually.

Key Points: 
  • Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the world’s first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system, today announced plans to present at the upcoming Oppenheimer 34th Annual Healthcare MedTech & Services Conference, taking place virtually.
  • Members of management are scheduled to present on Wednesday, March 13, 2024, at 2:40 pm ET.
  • The webcasts will be archived and available for replay for at least 90 days after the event.
  • For more information about the Swoop® Portable MR Imaging® system, please visit hyperfine.io .

Hyperfine, Inc. Announces Collaboration with Athletic Heart to Provide Vital Brain Health Imaging for Former Professional Athletes

Retrieved on: 
수요일, 2월 21, 2024
Basketball, Health, Sports, Neurology, Health Technology, General Sports, Biotechnology, Athletic heart syndrome, Multimedia, Hyperfine structure, Athletic, FDA, Quality of life, Safety, Patient, Athlete, Partnership, Medical imaging

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the world’s first FDA-cleared portable magnetic resonance (MR) brain imaging system–the Swoop® system, and Athletic Heart Cardiac and Metabolic Testing, LLC (Athletic Heart), a mobile medical diagnostic company providing streamlined, comprehensive testing for collegiate, professional, and former professional athletes, today announced a collaboration to bring portable brain imaging screenings to current and retired professional athletes, starting with retired professional basketball players.

Key Points: 
  • Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the world’s first FDA-cleared portable magnetic resonance (MR) brain imaging system–the Swoop® system, and Athletic Heart Cardiac and Metabolic Testing, LLC (Athletic Heart), a mobile medical diagnostic company providing streamlined, comprehensive testing for collegiate, professional, and former professional athletes, today announced a collaboration to bring portable brain imaging screenings to current and retired professional athletes, starting with retired professional basketball players.
  • View the full release here: https://www.businesswire.com/news/home/20240221890131/en/
    Hyperfine, Inc. has redefined brain imaging with the world’s first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system—the Swoop® system (Photo: Business Wire)
    Hyperfine, Inc. and Athletic Heart’s inaugural joint event occurred at an athlete health screening event on Saturday, February 17, 2024, prior to the All-Star game in Indianapolis.
  • Retired players underwent the new addition of brain screening using the Swoop® system to provide clinicians with a better understanding of the individual athlete's brain health and help inform medical decisions.
  • The safety and portability of our proprietary ultra-low-field MR technology make this uniquely possible.”
    Athletic Heart said, “While Athletic Heart’s primary focus has been cardiac health, the Hyperfine, Inc. Swoop® system extends our capabilities to include on-site brain imaging, which is a huge win for prevention and brain health.

Hyperfine, Inc. Celebrates Breadth of Swoop® System Data Presented at the 2024 International Stroke Conference and Provides an Update on Enrollment in ACTION PMR Stroke Observational Study

Retrieved on: 
목요일, 2월 1, 2024
Health, Medical Devices, Neurology, Health Technology, Radiology, Clinical Trials, Cardiology, Abstract, ISC, Massachusetts General Hospital, Hospital, Research, MD, ACTION, Patient, Stroke, Diagnosis, FDA, Hyperfine structure, Doctor of Philosophy, PMR, Conference, Medical imaging

These abstracts demonstrate the depth and breadth of research into the clinical utility and applications of portable ultra-low-field MR imaging.

Key Points: 
  • These abstracts demonstrate the depth and breadth of research into the clinical utility and applications of portable ultra-low-field MR imaging.
  • Conference attendees can learn more during the presentations listed below.
  • Maria Sainz, Hyperfine, Inc. president and CEO, said, “Acute ischemic stroke remains a large and growing global health issue.
  • Evaluating the opportunity for the Swoop® system to contribute to better stroke care remains incredibly compelling for our company.